Think of Ideapoint 19 an online matchmaker bringing biotech inventors and biopharma companies together. In one corner, toiling away in academic...

It could be the most grueling marathon in Olympic history -- and thats before you throw in Beijings feared summertime heat and smog.

Shares of Abbott Laboratories rose Thursday after regulators approved its drug-coated Xience V stent for sale. The Food and Drug Administration approved the stent late Wednesday, and Abbott expects it to take between 25 percent and 30 percent of the U.S. drug-coated stent market over the next 12 months.

http://us.news2.yimg.com/us.yimg.com/p/fi/17/23/48.jpg/yfinance/cnbc2/Government/783728437http://www.cnbc.com/http://l.yimg.com/us.yimg.com/i/us/fi/gr/partner_logos/cnbc_1.png

Abbott Laboratories will reach its market share goals for its drug-coated Xience V stent, analysts said Thursday. The Food and Drug Administration approved the stent late Wednesday, and Abbott expects it to take between 25 percent and 30 percent of the U.S. drug-coated stent market over the next 12 months.

Shares of Affymax Inc. fluctuated wildly Wednesday after an analyst predicted success for the company's drug candidate Hematide as a treatment for anemia caused by kidney disease.

Drug developer and medical device maker Abbott Laboratories said Wednesday it received Food and Drug Administration approval for its anticipated drug-coated stent, Xience V.

In a move widely anticipated by industry watchers, the Food and Drug Administration has approved Abbott Laboratories and Boston Scientifics new drug-coated coronary stent.

An entrepreneur with $60 million in venture funding says he's found an endless source of cheap energy. Trouble is, it violates the laws of quantum physics.